Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports

The acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is inevitable and heterogeneous. The strategies to overcome acquired resistance are significant. For patients with secondary T790M-positive after early generation EGFR-TKIs, osimertinib is the standard...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yue Zeng, Yuanqing Feng, Guihua Fu, Junlan Jiang, Xiaohan Liu, Yue Pan, Chunhong Hu, Xianling Liu, Fang Wu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-04-01
Colecção:	Frontiers in Pharmacology
Assuntos:	non-small-cell lung cancer EGFR-TKI acquired resistance T790M diver gene resistance ALK fusion MET amplification
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2022.838247/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!